Personalized treatment for CHCHD10 ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a personalized medicine approach for people with a specific genetic form of ALS caused by changes in the CHCHD10 gene. A custom-designed antisense oligonucleotide (a type of genetic therapy) is used to target the underlying cause of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis, specifically a change in the CHCHD10 gene linked to ALS.
- You need to be able to travel to the study site and attend follow-up visits.
- You or your legal representative must give informed consent to participate.
- You cannot be taking any other experimental medications within a certain time before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment designed for one patient with ALS (Lou Gehrig's disease) caused by a specific genetic change. The therapy aims to target the genetic cause, potentially slowing the disease, and this study will help learn if it's safe and beneficial.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial tests a medication called acamprosate to see if it can slow down ALS in people who have a specific genetic change (C9orf72). If you have this gene change and ALS, this study might offer a new treatment option.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and whether it can slow the progression of the disease.
This trial provides access to an experimental medicine called CNM-Au8 (a gold-based suspension) for people with ALS. The goal is to see if it can slow disease progression. It is an 'expanded access' program, which means it is for people who are not eligible for other clinical trials.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.